<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817605</url>
  </required_header>
  <id_info>
    <org_study_id>UVa</org_study_id>
    <nct_id>NCT04817605</nct_id>
  </id_info>
  <brief_title>Effects of Therapeutic Exercise in Patients With Fibromyalgia</brief_title>
  <official_title>Effects of Therapeutic Exercise in Patients With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Zaragoza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad de Zaragoza</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibromyalgia syndrome is characterized by chronic generalized musculoskeletal pain associated&#xD;
      with fatigue, sleep disturbances and some biochemical markers. The European League Againts&#xD;
      Rheumatism (EULAR) described an algorithm how to treat step by step these patients.&#xD;
&#xD;
      The objective of this trial is to evaluate if therapeutic exercise is effective on fatigue,&#xD;
      pain threshold, quality of life, quality of sleep, pain coping and biochemical and genetic&#xD;
      markers.&#xD;
&#xD;
      For this purpose, the investigators conduct a randomized controlled trial double-blind&#xD;
      (patient and examiner). The investigators included patients diagnosed of fibromyalgia&#xD;
      according to the American College of Rheumatology (ACR).&#xD;
&#xD;
      Patients included one group receiving exercise therapy consisting of 3 treatment sessions a&#xD;
      week over 10 weeks.&#xD;
&#xD;
      The variables are measured at the beginning and end of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">June 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>Baseline</time_frame>
    <description>VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>through study completion, an average 10 weeks</time_frame>
    <description>VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Sleep</measure>
    <time_frame>Baseline</time_frame>
    <description>The investigators measure the quality of sleep with Pittsburg Sleeping Questionnaire Index (PSQI) at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Sleep</measure>
    <time_frame>through study completion, an average 10 weeks</time_frame>
    <description>The investigators measure the quality of sleep with Pittsburg Sleeping Questionnaire Index (PSQI) at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pressure pain threshold</measure>
    <time_frame>Baseline</time_frame>
    <description>The investigators measure the pressure pain threshold of the 18 points described initially by the American College of rheumatology with a digital algometer at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain threshold</measure>
    <time_frame>through study completion, an average 10 weeks</time_frame>
    <description>The investigators measure the pressure pain threshold of the 18 points described initially by the American College of rheumatology with a digital algometer at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central sensitization</measure>
    <time_frame>Baseline</time_frame>
    <description>The investigators measure the central sensitization with Chronic Pain Self-Efficacy Scale (CPSS) at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central sensitization</measure>
    <time_frame>through study completion, an average 10 weeks</time_frame>
    <description>The investigators measure the central sensitization with Chronic Pain Self-Efficacy Scale (CPSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of tryptophan metabolites</measure>
    <time_frame>Baseline</time_frame>
    <description>The investigators measure the tryptophan metabolites with blood test analysis at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of tryptophan metabolites</measure>
    <time_frame>through study completion, an average 10 weeks</time_frame>
    <description>The investigators measure the tryptophan metabolites with blood test analysis at baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Therapeutic Exercise</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Exercise Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapeutic Exercise</intervention_name>
    <description>Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.</description>
    <arm_group_label>Exercise Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed medically with Fibromyalgia&#xD;
&#xD;
          -  Diagnosed according to the American College of Rheumatology criteria&#xD;
&#xD;
          -  Agreement to attend to treatment sessions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any kind of contraindications for physical activity&#xD;
&#xD;
          -  Other kind of diseases that could limit the intervention&#xD;
&#xD;
          -  Previous surgery last year&#xD;
&#xD;
          -  Medication modifications in the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sandra Jiménez Jiménez-del-Barrio</name>
      <address>
        <city>Soria</city>
        <zip>42004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra J Jiménez-del-Barrio, PhD</last_name>
      <phone>677231049</phone>
      <email>sandra.jimenez.barrio@uva.es</email>
    </contact>
    <contact_backup>
      <last_name>Luis C Ceballos-Laita, PhD</last_name>
      <phone>677380938</phone>
      <email>luis.ceballos@uva.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Zaragoza</investigator_affiliation>
    <investigator_full_name>Sandra Jiménez</investigator_full_name>
    <investigator_title>University of Valladolid Faculty of Health Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

